STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical ... and supports our sample size estimates for the trial and the interim ...

Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other ... were also observed in the Phase IIb clinical trial for HLA-A*02 only patients.

This global, open-label, randomized, phase III trial was conducted at 171 cancer treatment centers ... assessment available. The planned sample size and power calculations were based on the pMMR ...

“We plan to leverage these data to expand the existing P1101 product label and further expand ... M.D., Ph.D. added. Detailed clinical trial results will be presented at a later date and ...